76 related articles for article (PubMed ID: 12736763)
21. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.
Erlichman C; Hidalgo M; Boni JP; Martins P; Quinn SE; Zacharchuk C; Amorusi P; Adjei AA; Rowinsky EK
J Clin Oncol; 2006 May; 24(15):2252-60. PubMed ID: 16710023
[TBL] [Abstract][Full Text] [Related]
22. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study.
Zatloukal P; Petruzelka L; Zemanova M; Havel L; Janku F; Judas L; Kubik A; Krepela E; Fiala P; Pecen L
Lung Cancer; 2004 Oct; 46(1):87-98. PubMed ID: 15364136
[TBL] [Abstract][Full Text] [Related]
23. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
24. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
Münster P; Marchion D; Bicaku E; Schmitt M; Lee JH; DeConti R; Simon G; Fishman M; Minton S; Garrett C; Chiappori A; Lush R; Sullivan D; Daud A
J Clin Oncol; 2007 May; 25(15):1979-85. PubMed ID: 17513804
[TBL] [Abstract][Full Text] [Related]
25. Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
Schaefer PL; Marks RS; Mahoney MR; Sloan JA; Bauman MD; Tazelaar HD; Kugler JW; Mailliard JA; Ebbert LP; Wiesenfeld M
Am J Clin Oncol; 2003 Jun; 26(3):236-40. PubMed ID: 12796591
[TBL] [Abstract][Full Text] [Related]
26. Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study.
Hochster HS; Plimack ER; Mandeli J; Wadler S; Runowicz C; Goldberg G; Speyer J; Wallach R; Muggia F;
Gynecol Oncol; 2006 Feb; 100(2):324-9. PubMed ID: 16253316
[TBL] [Abstract][Full Text] [Related]
27. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
[TBL] [Abstract][Full Text] [Related]
28. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors.
Conley BA; Egorin MJ; Tait N; Rosen DM; Sausville EA; Dover G; Fram RJ; Van Echo DA
Clin Cancer Res; 1998 Mar; 4(3):629-34. PubMed ID: 9533530
[TBL] [Abstract][Full Text] [Related]
29. From the gut to the peripheral tissues: the multiple effects of butyrate.
Guilloteau P; Martin L; Eeckhaut V; Ducatelle R; Zabielski R; Van Immerseel F
Nutr Res Rev; 2010 Dec; 23(2):366-84. PubMed ID: 20937167
[TBL] [Abstract][Full Text] [Related]
30. Tributyrin: a prodrug of butyric acid for potential clinical application in differentiation therapy.
Chen ZX; Breitman TR
Cancer Res; 1994 Jul; 54(13):3494-9. PubMed ID: 8012972
[TBL] [Abstract][Full Text] [Related]
31. Review article: short chain fatty acids as potential therapeutic agents in human gastrointestinal and inflammatory disorders.
Gill PA; van Zelm MC; Muir JG; Gibson PR
Aliment Pharmacol Ther; 2018 Jul; 48(1):15-34. PubMed ID: 29722430
[TBL] [Abstract][Full Text] [Related]
32. Anticarcinogenic actions of tributyrin, a butyric acid prodrug.
Heidor R; Ortega JF; de Conti A; Ong TP; Moreno FS
Curr Drug Targets; 2012 Dec; 13(14):1720-9. PubMed ID: 23140283
[TBL] [Abstract][Full Text] [Related]
33. Prophylactic tributyrin treatment mitigates chronic-binge ethanol-induced intestinal barrier and liver injury.
Cresci GA; Glueck B; McMullen MR; Xin W; Allende D; Nagy LE
J Gastroenterol Hepatol; 2017 Sep; 32(9):1587-1597. PubMed ID: 28087985
[TBL] [Abstract][Full Text] [Related]
34. Tributyrin Attenuates Metabolic and Inflammatory Changes Associated with Obesity through a GPR109A-Dependent Mechanism.
Sato FT; Yap YA; Crisma AR; Portovedo M; Murata GM; Hirabara SM; Ribeiro WR; Marcantonio Ferreira C; Cruz MM; Pereira JNB; Payolla TB; Guima SES; Thomas AM; Setubal JC; Alonso-Vale MIC; Santos MF; Curi R; Marino E; Vinolo MAR
Cells; 2020 Sep; 9(9):. PubMed ID: 32882837
[TBL] [Abstract][Full Text] [Related]
35. The 2-monoacylglycerol moiety of dietary fat appears to be responsible for the fat-induced release of GLP-1 in humans.
Mandøe MJ; Hansen KB; Hartmann B; Rehfeld JF; Holst JJ; Hansen HS
Am J Clin Nutr; 2015 Sep; 102(3):548-55. PubMed ID: 26178726
[TBL] [Abstract][Full Text] [Related]
36. Tributyrin, a Butyrate Pro-Drug, Primes Satellite Cells for Differentiation by Altering the Epigenetic Landscape.
Murray RL; Zhang W; Liu J; Cooper J; Mitchell A; Buman M; Song J; Stahl CH
Cells; 2021 Dec; 10(12):. PubMed ID: 34943981
[TBL] [Abstract][Full Text] [Related]
37. Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches.
Williams LM; Cao S
Pharmacol Ther; 2024 Apr; 256():108605. PubMed ID: 38367866
[TBL] [Abstract][Full Text] [Related]
38. The Postbiotic Butyrate Mitigates Gut Mucosal Disruption Caused by Acute Ethanol Exposure.
Siddiqui MT; Han Y; Shapiro D; West G; Fiocchi C; Cresci GAM
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338944
[TBL] [Abstract][Full Text] [Related]
39. The Role of Gut Microbiome-Derived Short-Chain Fatty Acid Butyrate in Hepatobiliary Diseases.
Pant K; Venugopal SK; Lorenzo Pisarello MJ; Gradilone SA
Am J Pathol; 2023 Oct; 193(10):1455-1467. PubMed ID: 37422149
[TBL] [Abstract][Full Text] [Related]
40. Tributyrin Intake Attenuates Angiotensin II-Induced Abdominal Aortic Aneurysm in
Lin CP; Huang PH; Chen CY; Tzeng IS; Wu MY; Chen JS; Chen JW; Lin SJ
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
